Empower Your Health: Comprehensive BRCA1/2 Testing for Personalized Cancer Risk Assessment and Precision Oncology
The AmpliSeq for Illumina BRCA Panel is a targeted resequencing assay for research of somatic and germline variants across BRCA1 and BRCA2 genes. Key features include:
Relevant Gene Content
Target all exonic regions and flanking intronic sequences of BRCA1 and BRCA2
Fast, Streamlined Workflow
Prepare sequencing-ready libraries in a single day from as little as 1 ng of high quality or 10 ng of formalin-fixed, paraffin-embedded (FFPE) input samples
Detect somatic mutations as low as 5% variant allele frequency using local or cloud based analysis
BRCA1/2 germline mutation analysis (NGS) is employed to assist in determining the necessity of targeted therapy and whether more radical surgical interventions are required. Additionally, it is utilized to analyze the cancer risk associated with BRCA1/2 mutations within families.
- Diagnostic Support: Conducted on patients to determine the optimal precision oncology treatment.
- Predictive Analysis: Conducted on family members to assess the likelihood of inherited mutation risks.
- Tissue samples for patients
- Blood samples for family members
These examinations play a crucial role in tailoring oncological treatments for patients and assessing hereditary mutation risks within families, contributing to more informed and personalized healthcare decisions.